Health-related quality of life in a cohort of 1070 patients with hypoparathyroidism
Authors' conclusion
Thirty-six-Item Short-Form Health Survey version 2 scores in patients with cHypoPT were lower than the normalized values reported previously for the US population. Patients who were subsequently prescribed rhPTH (1-84) had worse baseline HRQoL scores than those in the conventional therapy group.
Study context
- Population
- Adults aged ≥18 years with chronic hypoparathyroidism on conventional therapy at enrollment, PARADIGHM registry before May 31, 2022; 80.7% female, 86.0% White; surgery the cause in 82.2%
- Participants
- 1,070 adults
- Exposure
- Patients who subsequently received rhPTH vs conventional therapy
- rhPTH (1-84)n = 102
- Conventional therapyn = 968reference
- Outcome
- HRQoL (SF-36v2, WPAI:SHP, HypoPT-SD) at enrollment
- Follow-up
- Baseline
Methodological detailsregistry-based, baseline data at enrollment
- Registry-based
- Baseline data at enrollment
Main finding
As reported in the abstract
SF-36v2 component scores, whole cohort (normative scores: 50)
SF-36v2 physical component score, mean (SD)
46.3
10.2
SF-36v2 mental component score, mean (SD)
47.6
11.5
Observational data: associations, not effects.
Further findings
Baseline health-related quality of life (HRQoL), rhPTH (1-84) vs conventional therapy
- Significantly worse baseline scores with rhPTH (1-84) for all SF-36v2 and Hypoparathyroidism Symptom Diary (HypoPT-SD) parameters and most WPAI parameters
Biochemical parameters · baseline
- Mean albumin-adjusted calcium, phosphate and calcium-phosphate product within target ranges
- No meaningful differences between the groups
Original publication
Health-related quality of life in a cohort of 1070 patients with hypoparathyroidism. Eur J Endocrinol. Published 7 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →